Details

Autor(en) / Beteiligte

• Willis, Mark D.
• Pickersgill, Trevor P.
• Robertson, Neil P.
• Lee, Richard W. J.
• Dick, Andrew D.
• Carreño, Ester

Titel

Alemtuzumab-induced remission of multiple sclerosis-associated uveitis

Ist Teil von

• International ophthalmology, 2017-10, Vol.37 (5), p.1229-1233

Ort / Verlag

Dordrecht: Springer Netherlands

Erscheinungsjahr

2017

Link zum Volltext

Quelle

SpringerLink (Online service)

Beschreibungen/Notizen

• Purpose The purpose of the study was to report a case of multiple sclerosis (MS)-associated uveitis refractory to conventional immunosuppressants, with subsequent remission following treatment with alemtuzumab. Methods Case report Patient was treated with intravenous alemtuzumab, a lymphocyte depleting anti-CD52 monoclonal antibody that has recently been approved for use in relapsing MS. Results A 17-year-old female presented with bilateral optic neuritis and subsequently bilateral intermediate uveitis and secondary macular oedema. She was diagnosed with active relapsing MS for which she received treatment with alemtuzumab. The intraocular inflammation previously refractory to conventional immunosuppressants responded to alemtuzumab, inducing remission. Conclusions To our knowledge, this is the first such report of alemtuzumab treatment in MS-associated ocular inflammatory disease and may demonstrate a potential utility for this drug in related conditions.